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Usage and usability of one dry powder inhaler compared to 
other inhalers at therapy start: an open, non-interventional 
observational study in Poland and Germany
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Abstract
Introduction: Inhalation is the preferred route of drug administration for patients with asthma or COPD. It is generally predicted that there 
is a high error rate in inhaler usage, especially at the therapy start. The primary objective of this study was the validation of a questionnaire 
that can be used for assessing a successful inhalation technique, patient satisfaction as well as the compliance in daily practice.The sec-
ondary objective was to examine the “real-life” usage of one inhalation device in comparison with other devices at the start of the therapy. 
Material and methods: This open, multi centre and non-interventional study was designed to examine usage and usability of dry powder 
inhaler Easyhaler® (EH) (Orion Pharma, Finland) and other inhalers assessed by the physicians as well as by the patients.
Inclusion criteria for patients were a physician-diagnosis of COPD or asthma or children with asthmatic disease, therapy start with an 
inhalation device and no or only few experiences with inhaler usage (inhaler usage for not more than 3 months). Each physician enrolled 
an equal number of patients in each group.
Results: 263 adult/adolescent patients with asthma and 115 with COPD as well as 164 children with asthmatic disease were enrolled. 
49.4% of the adult/adolescent patients with asthma used an EH and 50.6% other inhalers. In the case of COPD, 47.8% were treated with 
an EH and 52.2% used other inhalation devices. Finally, 50.6% of the children with asthmatic disease used an EH and 49.4% were treated 
with other inhalers.
Inhaler usage, patient satisfaction, compliance and patients assessments of usability were better when the patients used an EH. Inconve-
nient features were mainly documented for other inhalers. The analysis of Cronbachs alpha clearly showed the consistency of the received 
data from all patients. In addition, there was a large association between the assessment of the inhaler usage and the general assessment 
of the used inhaler in all patient groups.
Conclusion: The results of this study show that investigators found EH easy to teach, the patients found it easy to use and their satisfaction 
with the device was high in comparison to other inhalation devices. Thus EH can be matched to many patients already at the therapy 
start. In addition, the high consistency of the received data and large association of the assessment of the inhaler usage and the general 
assessment of the inhaler indicate that the used questionnaires were appropriate tools to examine usage and usability of inhaler devices 
in adult patients and children. 
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Introduction 
Asthma and chronic obstructive pulmonary 
disease (COPD) are two of the most common 
pulmonary diseases worldwide [1, 2]. This gives 
rise to not only tremendous economic conse-
quences, since COPD is predicted to be the third 
most common cause of death in 2020 [3]. There-
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fore an effective treatment is very important. 
The long-term goals of asthma treatment are to 
achieve good symptom control, maintain nor-
mal activity levels, improve quality of life, and 
to minimize future risks of adverse outcomes, 
particularly exacerbations and fixed airflow lim-
itations. Pharmacologic therapy of COPD is used 
to reduce symptoms, prevent disease progression 
and exacerbations, reduce mortality, as well as 
improve health status and exercise tolerance. All 
these goals should be reached with minimal side 
effects from medications. Thus, inhalation is the 
preferred route of drug administration for patients 
with asthma or COPD [1, 2], because the dose can 
be small compared with oral therapy, and the risk 
of systemic side effects is reduced. Furthermore, 
direct delivery to the airways also results in more 
rapid bronchodilation than oral treatment [4]. 
For the best outcome, regular daily controller 
treatment should be initiated as soon as possible 
after the diagnosis is made, as evidence suggests 
that early initiation of low dose inhaled corticos-
teroids in patients with asthma leads to greater 
improvement in lung function than if symptoms 
have been present for more than 2−4 years [1].
There are a large number of inhalation devic-
es available. The effectiveness of inhaled drugs 
can be influenced by several factors, for example 
age, education, duration, severity of disease, type 
of inhaler used, inhalation technique, and use of 
several inhalers [5, 6]. Daily practice unfortunate-
ly shows a poor control of symptoms for many pa-
tients due to problems with drug administration 
that limit effectiveness of therapy. Differences 
in effectiveness of inhalers have clinical impli-
cations [7]. It is generally predicted that there 
is an error rate of 50% to 90% in inhaler usage, 
especially at the therapy start [8]. Easy and reli-
able inhalation may improve inhaler competence 
and adherence to prescribed medications. Clin-
ical evaluations have indicated that Easyhaler® 
(EH) comes close to an “ideal inhaler” including 
a consistent fine particle dose across a wide range 
of inspiratory flow rates, high lung desposition 
and patient preferences [9, 10]. Several studies 
have shown a good inhaler competence and pa-
tient satisfaction with EH also in real-life settings 
[11−13]. However, usage and usability as well as 
patient satisfaction and adherence have not been 
tested with a patient population who start their 
therapy of asthma or COPD, because experiences 
with inhalation devices may have an influence on 
inhalation technique and effectiveness of therapy. 
In the long-term perspective there are surely also 
healthcare and economic advantages to prevent 
substitution of an inhalation drug together with 
the connected application errors by selecting the 




This open, multi-centre and non-interven-
tional study was designed to validate a ques-
tionnaire and to examine usage and usability of 
EH (Orion Pharma, Finland) and other inhalers 
assessed by the physicians as well as by the pa-
tients. The questionnaire was designed and pro-
posed by an independent advisory board including 
a pulmonologist, a pediatrician, a pharmacist and 
a respiratory nurse. The advisory board recom-
mended the questionnaire for further evaluation. 
The study was carried out with resident physi-
cians in Germany and Poland and was conducted 
in agreement with the regulations of the German 
and Polish Drug Laws and the relevant legal ob-
ligations for data processing and data protection 
in both countries. In addition, the study was 
submitted to the independent Ethics Commission 
International in Freiburg, Germany, and received 
a positive vote. The Polish Office for Medicinal 
Products in Warsaw, Poland was notified accord-
ing to the current local regulations.
Primary and secondary objectives
The primary objective of the study was to 
validate a questionnaire that can be used for 
assessing a successful inhalation technique as 
well as the compliance of the patient in daily 
practice. This questionnaire should be suitable 
for all populations, from the children up to the 
multi morbid elderly patients and should help 
finding the best choice of device for every patient.
The secondary objective was to examine 
usage and usability of EH compared with other 
inhalers at the start of therapy with an inhalation 
device in asthma and COPD patients.
Patients
Inclusion criteria for patients were: adults 
with physician-diagnosed COPD or asthma, chil-
dren with asthmatic disease, therapy started with 
an inhalation device and no or only few expe-
riences with inhaler usage (inhaler naïve patients 
— inhaler usage for less than 3 months), ability 
to read and understand instructions (respectively 
in German or Polish language). Exclusion criteria: 
inhaler usage for more than 3 months, contrain-
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dications according to product characteristics, 
participation in other clinical studies. Selection 
of patients was at physician’s own discretion 
taking into account the respective summaries of 
product characteristics. Physicians were advised 
to diagnose and treat asthma or COPD according 
to current guidelines [1, 2]. All patients included 
to the study were inhaler naïve irrespectively of 
the time from the diagnose. Patients with a known 
intolerance to the active agents of the respective 
inhalers or milk proteins could not be included in 
the study. Each physician should enrol an equal 
number of EH-patients and patients with other in-
halation devices. Overall, 54 German centres and 
43 Polish centres enrolled 263 adult/adolescent 
patients with asthma (in Poland: 177 patients, 
in Germany: 86 patients), 115 adult patients 
with COPD (in Poland: 71 patients, in Germany: 
44 patients) and 164 children (≤ 12 years old) 
with asthmatic disease (in Poland: 136 children, 
in Germany: 28 children). 49.4% (130) of the 
adult/adolescent patients with asthma used an 
EH and 50.6% other inhalers (133). In the case of 
COPD, 47.8% (55) were treated with an EH and 
52.2% (60) used other inhalation devices. Finally, 
50.6% (83) of the children with asthmatic disease 
used an EH and 49.4% (81) were treated with 
other inhalers.
Procedure
Patients were informed of the nature of the 
study and gave their written consent to parti-
cipate. Documentation was recorded at three 
consecutive time points: at the initial visit (visit 
0), and at 2 weeks (visit 1) and 8 weeks (visit 2) 
thereafter. In the initial visit, physicians recorded 
demographic data, including date of diagnosis, 
disease severity, comorbidities, smoking habits, 
education, and used inhaler. In addition, they 
described their experiences with the inhaler 
training at therapy start. In the following two 
visits the physicians documented their general 
assessment of the inhaler handling, the patient’s 
compliance as well as the occurrence of adverse 
events. Adult/adolescent patients were requested 
to fill out the 7-item questionnaire concerning 
the inhaler usage in all visits, including inhaler 
training, preparation of the inhaler for utilization, 
inhaler handling, success of inhalation, cleaning 
of the inhaler, daily activities with the inhaler 
(e.g. sports) as well as size and weight. Children 
received a 5-item questionnaire. They should also 
assess how easy it was to learn the usage of their 
inhalers and how easy it was to take along the in-
haler everywhere as well as the inhaler handling 
in daily practice. In addition, they were asked of 
the ease of breathing in and the functionality of 
the inhaler even when the children did not take 
good care of it while playing. The parents or legal 
guardians of the children were asked to fill in 
the same questionnaire. The assessment of the 
items was made according to school marks (Ger-
many: 1 = very good to 6 = insufficient, Poland: 
1 = insufficient to 6 = very good). For analysis, 
the Polish school mark system was converted into 
the German system and the school marks of the 
5 (children) or 7 (adult patients) items concerning 
the inhaler usage were summarized and divided 
by 5 or 7, respectively to get the Inhaler Usage 
Score. In addition, the patients should assess their 
respective inhalers in general. This assessment 
was also made according to school marks. Further-
more, the patients could document inconvenient 
features of the inhaler (none, smell, taste, cough, 
hoarseness or other (could be specified by the pa-
tient)) and they were asked how often they used 
the inhaler per day (Table 1). 
Statistical analysis
Statistical analysis was performed by using 
SAS for Windows (Statistical Analysis System, 
SAS Institute, Cary NC, USA). The biometric 
analysis comprised an elementary descriptive 
statistical evaluation of all collected criteria. Part 
of the qualitative criteria were the number of 
cases, the absolute and the relative frequency of 
each characteristic. The quantitative criteria were 
the number of cases as well as mean, maximum, 
minimum, median 1st quantile, 3rd quantile, stan-
dard error and standard deviation. User-defined 
texts were transferred into suitable coding sche-
mes. Each item of the descriptive statistic was 
stratified by used inhaler and/or by diagnosis. In 
order to evaluate and verify the questionnaire 
the correlation between the answers concerning 
inhaler usage and the general assessment of the 
inhaler documented by the patients was analy-
zed (Pearson Correlation Coefficient r). The con-
sistency of the answers in the questionnaires was 
evaluated by using Cronbachs alpha analysis. In 
order to evaluate possible significant differences 
in the assessment of the inhaler usage between 
patients with an EH and patients with other in-
halers, the results documented in the patient’s 
questionnaire were analyzed by using Student’s 
t-tests (significance level p = 0.05). For this analy-
sis, the grades of every question related to inhaler 
usage were reassessed. The school mark 1 was 
reassessed as grade “very good” with value 1 and 
the school marks 2 to 6 were combined to one 
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Table 1. Items of patient’s questionnaires (assessment according to school marks: 1 (very good) to 6 (insufficient), Polish 
system was converted into German system)
Children Adult/adolescent patients
Inhaler Usage Score
1. How easy was it for you to learn the handling of your inhaler? 1. How easy was it to learn the inhaler usage?
2. How easy is it for you to use your inhaler every day? 2. How easy is it to prepare the inhaler for utilization?
3. How easy is breathing-in for you when you inhale? 3. How easy is it to handle/operate the inhaler, even in everyday 
situations?
4. How easy is it for you to take along your inhaler everywhere? 4. How easy is a successful inhalation, even in everyday situations.
5. Does the inhaler work well even when you did not take good care 
of it while playing?
5. How easy is it to keep the inhaler clean and ready-to-use?
6. How easy are daily activities (e.g. sports) with the inhaler?
7. How easy is it to handle the inhaler and carry it along regarding 
its size and weight?
Inconvenient features/inhalation frequency
None, Smell, Taste, Cough, Hoarseness
Other (specified by patient)
None, Smell, Taste, Cough, Hoarseness
Other (specified by patient)
How often did you inhale daily? How often did you inhale daily?
General assessment of the inhaler
How do you like your inhaler in general? How would you assess your inhaler in general according to school 
marks?
grade “not very good” with value 2. Thereafter, 
a new Inhaler Usage Score was calculated with 
the reassessed values, the so-called combined 
Inhaler Usage Score. 
Results
There was a total of 542 patients included 
in the study. Demographic data of these patients 
are shown in Table 2 divided by age (child-
ren ≤ 12 years old, and adult and adolescent 
patients > 12 years old). The most frequently 
mentioned other inhalers prescribed were Disc 
(children: 29.2%, adult/adolescent patients: 
19.2%), metered dose inhaler (MDI, children: 
4.9%, adult/adolescent patients: 16.1%) and 
Turbuhaler® (children: 23.2%, adult/adolescent 
patients: 16.6%). However the physicians were 
not only advised to treat asthma/COPD patients 
according to current guidelines but also to 
follow the respective product characteristics, 
the off-label use of the inhalers in paediatric 
population was not an exclusion criterion from 
the study. 
The vast majority of the included children 
attended the elementary school (88.4%) and 6.7% 
the secondary school. Most of the adult/adole-
scent patients had higher graduations, in 43.4% of 
the cases an university entrance qualification was 
documented, only 3.2% of the adult/adolescent 
patients were without graduation.
Physician’s assessment of inhaler training, 
inhaler usage and patient’s compliance of 
the included children
For 88.0% of the included children that used 
an EH and 71.6% of the children with other inha-
lation devices the physician reported that it was 
very easy or fairly easy to teach the correct use 
of the respective inhaler. The correct use of the 
inhaler was achieved with one demonstration in 
60.2% of the children with EH and in 50.6% of 
the children with other inhalers. Training was 
reported to be hard for one child, that did not 
use the EH. The respective instruction manual 
was widely comprehensible (EH: 96.4%, other 
inhalers: 87.7%) (Table 3).
In most of the cases the inhaler handling was 
well integrated into the young patient’s everyday 
life at visit 1 (89.6%) and visit 2 (93.3%) but the 
assessment of the inhaler usage by the physician 
was better when the children were treated with 
the EH (visit 1: 94.0%, visit 2: 97.6% vs. other 
inhalers: visit 1: 85.0%, visit 2: 88.9%). In ac-
cordance to that, the physician indicated more 
difficulties in the inhaler handling when the 
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Table 2. Demographic data of the patients
Children Adult/adoles-
cent patients
No. of patients 164 378
Gender
 Male, n (%) 89 (54.3) 184 (48.7)
 Female n (%) 71 (43.3) 189 (50.0)
 Not reported n (%) 4 (2.4) 5 (1.3)
Mean age, years (SD) 9,6 (1,9) 49.4 (18.3)
Age range, years 3-12 13−88
Diagnosis
 Asthma, n (%) 164 (100.0) 263 (69.6)
 COPD, n (%) NR 115 (30.4)
Diagnosis known since, mon-
ths (SD)
34.8 (31.8) 53.5 (55.6)
Mean asthma severity*, grade 
(SD)
1.9 (0.6) 2.1 (0.6)
Mean COPD severity**
 Stage A (mild), n (%) NR 7 (6.1)
 Stage B (moderate), n (%) NR 55 (47.8)
 Stage C (severe), n (%) NR 31 (27.0)
 Stage D (very severe), n (%) NR 16 (13.9)
 Not reported, n (%) NR 6 (5.2)
Comorbidities***
 neurological, n (%) 1 (0.6) 13 (3.4)
 other, n (%) 30 (18.3) 129 (34.1)
 none, n (%) 133 (81.1) 247 (65.3)
Smoking habits
 Smoker NR 68 (18.0)
 Former smoker, n (%) NR 109 (28.8)
 Non-smoker n (%) NR 199 (52.6)
Used inhaler
 EH, n (%) 83 (50.6) 185 (48.9)
 Other inhaler, n (%) 81 (49.4) 193 (51.1)
*based on Expert Panel Report 2, National Asthma Education and Prevention 
Program [14, 15] grade 1 to 4, **based on GOLD grading system (2) stage 
A,B,C,D; ***multiple nominations possible, NR = not registered
Table 3. Physician’s assessment of the inhaler training in 
visit 0 for the children with asthmatic disease 
divided by used inhaler 
EH n (%) Other inhaler n (%)
No. of patients 83 81
Ease of teaching the correct use of the inhaler (p < 0.05)
Very easy 33 (39.8) 21 (25.9)
Fairly easy 40 (48.2) 37 (45.7)
Somewhat easy 10 (12.0) 14 (17.3)
Not very easy 0 5 (6.2)
Hardly at all 0 1 (1.2)
Not reported 0 3 (3.7)
Was it necessary to repeat the training? (p = NS)
Yes 33 (39.8) 38 (46.9)
No 50 (60.2) 41 (50.6)
Not reported 0 2 (2.5)
Was the instruction manual comprehensible? (p = NS)
Yes 80 (96.4) 71 (87.7)
No 3 (3.6) 8 (9.9)
Not reported 0 2 (2.5)
patients used other inhalers (EH: visit 1: 4.8%, 
visit 2: 3.6% vs. other inhalers: visit 1: 12.5%, 
visit 2: 9.9%). Similar differences could be found 
when the data of the patient’s compliance were 
analyzed. In visit 1, the physicians reported 
a very good or good compliance for 96.4% of the 
patients with an EH (other inhalers: 90.0%). In 
visit 2, 98.8% of the children with an EH showed 
a very good or good compliance (other inhalers: 
87.7%) (Fig. 1).
Physician’s assessment of inhaler training, 
inhaler usage and patient’s compliance of 
the included adult/adolescent patients
Overall, for 81.6% of adult/adolescent pa-
tients with an EH but only for 64.8% of the pa-
tients with other inhalers the physician reported 
that it was very easy or fairly easy to teach the 
use of the respective inhaler. Interestingly, it was 
easier to teach patients with asthmatic disease 
(80.2%) than COPD patients (56.5%). Only one 
demonstration of the correct use of the inhaler 
was documented for 63.8% but in 52.3% of the 
patients with other inhaler. Patients with COPD 
needed more often a repetition of the training 
(56.5% vs. patients with asthma: 35.4%). Con-
cerning the comprehensibility of the respective 
instruction manuals no differences could be 
found. The manuals were comprehensible in the 
vast majority of the cases (Table 4).
The inhaler handling in the patient’s every-
day life was in the most cases very good or good 
(EH: visit 1: 88.6%, visit 2: 90.7%; other inhalers: 
visit 1: 80.8%, visit 2: 85.5%). There were no 
differences concerning the diagnosis. Overall, in 
five cases the physicians indicated a bad inhaler 
handling. All these patients were affected by 
asthma and used an EH. However, the occurrence 
of difficulties in the inhaler handling were less 
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Table 4.  Physician’s assessment of the inhaler training at visit 0 for the adult patients divided by used inhaler and diagno-
sis 
EH n (%) Other inhaler 
n (%)
Asthma n (%) COPD n (%)
No. of patients 185 193 263 115
Ease of teaching the correct use of the inhaler
Very easy 65 (35.1) 40 (20.7) 95 (36.1) 10 (8.7)
Fairly easy 86 (46.5) 85 (44.0) 116 (44.1) 55 (47.8)
Somewhat easy 24 (13.0) 59 (30.6) 45 (17.1) 38 (33.0)
Not very easy 5 (2.7) 6 (3.1) 3 (1.1) 8 (7.0)
Hardly at all 1 (0.5) 0 1 (0.4) 0
Not reported 4 (2.2) 3 (1.6) 3 (1.1) 4 (3.5)
(p < 0.01)* (p < 0.01)**
Was it necessary to repeat the training?
Yes 66 (35.7) 92 (47.7) 93 (35.4) 65 (56.5)
No 118 (63.8) 101 (52.3) 170 (64.6) 49 (42.6)
Not reported 1 (0.5) 0 0 1 (0.9)
 (p < 0.05)*  (p < 0.01)**
Was the instruction manual comprehensible?
Yes 178 (96.2) 177 (91.7) 247 (93.9) 108 (93.9)
No 6 (3.2) 16 (8.3) 15 (5.7) 7 (6.1)
Not reported 1 (0.5) 0 1 (0.4) 0
 (p < 0.05)*  (p = NS)**
COPD — chronic obstructive pulmonary disease 
*between EH and other inhaler 
**between Asthma and COPD
Figure 1. Physician’s assessment of inhaler handling in patient’s everyday life, occurrence of difficulties in inhaler handling and patient’s complian-
ce of included children in two visits in the study divided by used inhaler, integration of inhaler usage: relative frequencies of very good and good 
assessments by the physicians, patient’s compliance: very good and good assessments by the physician; EH: N (visit 1): 83, N (visit 2): 83; other 
inhaler: N (visit 1): 81, N (visit 2): 80 
p-values adjusted for visit
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frequently documented when patients used an 
EH (visit 1: 4.9%, visit 2: 1.1% vs. other inhalers: 
visit 1: 13.0%, visit 2: 9.3%). Interestingly, at 
visit 1 there were clearly more difficulties in the 
inhaler handling at the group of COPD patients 
(14.0% vs. asthma: 6.8%), but these differences 
disappeared at visit 2 (COPD: 4.4% vs. asthma: 
5.7%). Similar to the data of the children, the 
compliance of the adult/adolescent patients with 
an EH was better than the compliance of patients 
with other inhalation devices (Fig. 2).
Assessment of inhaler usage and general 
assessment of the inhaler by the children 
and their parents or legal guardians
In total, the children used their respective 
inhaler in the mean two times per day. This 
inhalation frequency did not change during the 
observation period. In addition, there were no 
differences regarding the used inhalers (visit 0: 
2.2 ± 0.9 inhalations per day, visit 1: 2.1 ± 0.8 in-
halations per day, visit 2: 2.3 ± 1.1 inhalations 
per day).
The assessment of the inhaler usage by the 
children and their parents or legal guardian were 
very similar. In all visits, the Inhaler Usage Score 
for EH was better than for the other inhalation 
devices. The best Inhaler Usage Score was do-
Figure 2. Physician’s assessment of inhaler handling in patient’s everyday life, occurrence of difficulties in inhaler handling and patient’s compliance 
of included adult patients in two visits in the study divided by used inhaler and diagnosis, integration of inhaler usage: relative frequencies of very 
good and good assessments by the physicians, patient’s compliance: very good and good assessments by the physician; EH: N (visit 1): 184, N 
(visit 2): 183; other inhaler: N (visit 1): 191, N (visit 2): 193; asthma: N (visit 1): 263, N (visit 2): 262, COPD: N (visit 1): 114, N (visit 2): 114 
COPD — chronic obstructive pulmonary disease
*between EH and other inhaler
**between asthma and COPD
cumented for EH at visit 2 (children: 1.6 ± 0.5, 
parents/legal guardian: 1.7 ± 0.5). For the other 
inhalation devices the children documented an 
Inhaler Usage Score of 2.0 ± 0.9 at visit 2 (pa-
rents/legal guardian: 2.1 ± 0.8) (Fig. 3). However, 
the combined Inhaler Usage Score showed no 
significant differences between the assessments of 
EH and of the other inhalation devices (Table 5).
In accordance to the Inhaler Usage Score, 
the general assessment of the EH was better than 
the assessment for other inhalers. At visit 2 the 
children indicated 1.6 ± 0.7 according to school 
marks and their parents or legal guardians repor-
ted 1.6 ± 0.6. The general assessment by the chil-
dren for other inhalation devices was 1.9 ± 0.9 at 
visit 2 according to school marks (parents/legal 
guardian visit 2: 2.1 ± 0.9) (Fig. 4).
Inconvenient features were documented 
more often when the children used other inha-
lers. At visit 0, 28.8% of the young patients with 
other inhalation devices reported inconvenient 
features, at visit 1 in 22.2% and at visit 2 25.0%. 
In contrary, only 16.9% of the patients with an EH 
noticed inconvenient features at visit 0, 10.8% in 
visit 1 and 8.4% at visit 2. The most frequently 
documented inconvenient feature was bad taste. 
In order to evaluate the consistency of the 
received data, the Cronbachs alpha coefficient 
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Figure 3. Inhaler usage score documented by the children and their parents/legal guardians in visit 0, visit 1 and visit 2 divided by used inhaler, 
inhaler usage score as mean average mark: 1 = very good to 6 = insufficient, the score was calculated by summarizing the documented school 
marks documented for the five questionnaire items concerning inhaler usage (inhaler training, inhaler handling, daily activities, breathing in and 
stability) and division by 5. children: EH: N = 83, other inhaler: N = 79; parents/legal guardians: EH: N = 83, other inhaler: N = 78
p-values adjusted for visit
was calculated. The calculation was based on 
463 questionnaires filled by the children and 
467 questionnaires filled by the parents or legal 
guardians at all three visits. The internal con-
sistency of the questionnaires was excellent. The 
received standardized value of alpha was 0.93 for 
both, the children’s questionnaires and the ques-
tionnaires for the parents/legal guardians. The 
linear correlation between the inhaler usage 
score and the general assessment was 0.77 for 
the results of the questionnaires documented by 
the children and 0.80 for the data from the ques-
tionnaires for parents/legal guardians. In both 
cases, there was a large linear association between 
Inhaler Usage Score and general assessment of 
the respective inhalers (Table 6).
Table 5.  Combined Inhaler Usage Score and results of Student’s t-tests (combined Inhaler Usage Score EH vs. other inha-
lers, significance level, p = 0.05); Children: N (visit 0): 163, N (visit 1): 164, N (visit 2): 163; Parents/ legal guar-
dian: N (visit 0): 162, N (visit 1): 164, N (visit 2): 163; Adult/adolescent patients: N (visit 0): 378, N (visit 1): 376, 
N (visit 2): 375, Adult/adolescent patients with asthma and children: N (visit 0): 426, N (visit 1): 427, N (visit 2): 
425, Adult patients with COPD: N (visit 0): 115, N (visit 1): 113, N (visit 2): 113, Adult/adolescent patients and 
children: N (visit 0): 541, N (visit 1): 540, N (visit 2): 538
Visit 0 Visit 1 Visit 2
EH OI p EH OI p EH OI p
Children 1.6 ± 0.4 1.7 ± 0.4 0.1941 1.6 ± 0.4 1.6 ± 0.4 0.2256 1.6 ± 0.4 1.6 ± 0.4 0.3794
Parent/legal guardian 1.7 ± 0.4 1.8 ± 0.4 0.3489 1.7 ± 0.4 1.7 ± 0.4 0.9247 1.6 ± 0.4 1.7 ± 0.4 0.2038
Adult/adolescent  
patients
1.7 ± 0.4 1.8 ± 0.4 0.0153 1.6 ± 0.4 1.7 ± 0.4 0.0004 1.5 ± 0.4 1.7 ± 0.4 < .0001
Adult/adolescent  
patients with asthma 
and children
1.6 ± 0.4 1.7 ± 0.4 0.0103 1.5 ± 0.4 1.7 ± 0.4 0.0007 1.5 ± 0.4 1.6 ± 0.4 0.0010
Adult patients with 
COPD
1.8 ± 0.3 1.9 ± 0.3 0.3810 1.7 ± 0.4 1.8 ± 0.4 0.3051 1.6 ± 0.4 1.8 ± 0.4 0.0653
Adult/adolescent  
patients and children
1.7 ± 0.4 1.8 ± 0.4 0.0054 1.6 ± 0.4 1.7 ± 0.4 0.0003 1.5 ± 0.4 1.7 ± 0.4 0.0001
COPD — chronic obstructive pulmonary disease, OI — other inhaler
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inhaler/asthma: 2.2 ± 1.0, other inhaler/COPD: 
2.0 ± 0.4).
The patients that used an EH assessed the 
usage of the inhaler better than the patients with 
other inhalation devices but there were differenc-
es in the score in connection with the diagno-
sis. The best score was documented in visit 2 by 
patients with asthma that used an EH (1.5 ± 0.6). 
COPD patients with an EH assessed the inhaler 
at beginning of the study not that good, but the 
score improved during the observation period. In 
visit 0, there was a mean Inhaler Usage Score of 
2.4 ± 0.8 and in visit 2 it was 1.7 ± 0.5. The same 
could be found for the patients that were treated 
with other inhalers. Patients with asthma (visit 
2: 1.9 ± 0.7) assessed their respective inhaler 
better than patients with COPD (visit 2: 2.1 ± 0.7) 
(Fig. 5). Overall, the analysis of the combined 
inhaler usage score of the patients with an EH 
compared to those with other inhalers showed 
significantly better assessments for EH, but that 
was dependent on the diagnosis. The combined 
Inhaler Usage Scores of COPD patients with EH 
and other inhalers showed no significant differ-
ences (Table 5). The results were confirmed by 
the general assessment of the inhalers. The best 
assessments were documented at visit 2 by the 
patients that were affected by asthma and used 
an EH (1.6 ± 0.7 vs. other inhalers: 1.9 ± 0.8). 
Patients with COPD and EH documented a mean 
school mark of 1.7 ± 0.6 at visit 2 (vs. other in-
halers: 2.2 ± 0.8) (Fig. 6).
Figure 4. General assessment of the inhaler documented by the children and their parents/legal guardians in visit 0, visit 1 and visit 2 divided by 
used inhaler, mean school mark: 1 = very good to 6 = insufficient, children: EH: N = 83, other inhaler: N = 79; parents/legal guardians: EH: N = 
83, other inhaler: N = 78
p-values adjusted for visit
Table 6.  Pearson Correlation Coefficient r (correlation 
between Inhaler Usage Score and general as-
sessment of the inhaler) and Cronbachs alpha 







Pearson Correlation Coefficient r
Number of questionnaires 463/ 462 1066
r value 0.77/ 0.80 0.85
Cronbachs alpha 
Number of questionnaires 465/ 467 1076
alpha value (standardized) 0.93/ 0.92 0.95
Assessment of inhaler usage and general 
assessment of the inhaler by the adult/ 
/adolescent patients
The adult/adolescent patients used their 
respective inhalers in the mean also two times 
per day. This inhalation frequency did not 
change during the study (visit 0: 2.1 ± 0.7 in-
halations per day, visit 1: 2.2 ± 1.0 inhalations 
per day, visit 2: 2.2 ± 1.0 inhalations per day). 
In addition, differences regarding used inhal-
er and diagnosis could not be found (visit 2: 
EH/asthma: 2.3 ± 1.2, EH/COPD: 2.2 ± 0.5, other 
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Figure 5. Inhaler Usage Score documented by the adult/adolescent patients in visit 0, visit 1 and visit 2 divided by used inhaler and diagnosis, 
inhaler usage score as mean average mark: 1 = very good to 6 = insufficient, the score was calculated by summarizing the documented school 
marks for the seven questionnaire items concerning inhaler usage (inhaler training, preparation for utilization, inhaler handling, success of inhalation, 
daily activities, cleaning of the inhaler, size and weight) and division by 7. EH/asthma: N = 129, EH/COPD: N = 53; other inhaler/asthma: N = 133, 
other inhaler/COPD: N = 59 
COPD — chronic obstructive pulmonary disease
*adjusted for visit and test between EH/asthma and other inhaler/asthma
**adjusted for visit and test between EH/COPD and other inhaler/COPD
Figure 6. General assessment of the inhaler documented by the adult/adolescent patients in visit 0, visit 1 and visit 2 divided by used inhaler and 
diagnosis, mean school mark: 1 = very good to 6 = insufficient, EH/asthma: N = 129, EH/COPD: N = 53; other inhaler/asthma: N = 133, other 
inhaler/COPD: N = 59 
COPD — chronic obstructive pulmonary disease
*adjusted for visit and test between EH/asthma and other inhaler/asthma
**adjusted for visit and test between EH/COPD and other inhaler/COPD
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The most inconvenient features were doc-
umented by the adult patients that used other 
inhalers (visit 0: 29.3% of patients with asthma 
and 30.0% of COPD patients, visit 1, 24.1% of 
patients with asthma and 35.0% of patients with 
COPD, visit 2 in 24.1% of the patients with asthma 
and in 28.8% of the patients with COPD). The 
proportion of patients that indicated inconvenient 
features of an EH was clearly lower (visit 0: 17.7% 
of patients with asthma and 9.1% of patients with 
COPD, visit 1 11.5% of patients with asthma and 
9.4% of patients with COPD, visit 2: 10.9% of 
patients with asthma and 5.6% of patients with 
COPD). The most frequently documented features 
were bad taste and the occurrence of hoarseness.
The calculation of the internal consistency by 
using Cronbachs alpha was based on 1,129 filled 
questionnaires from adult/adolescent patients 
during the observation period. The received 
standardized value of alpha was 0,96. Similar 
to the data from the children and parents/legal 
guardian, the internal consistency of the data 
from the adult patient’s questionnaire was ex-
cellent. That was confirmed by the Pearson cor-
relation coefficient r, which was approximately 
0.85. Thus, there was a large correlation between 
the Inhaler Usage Score and the general assess-
ment of the inhalers (Table 6).
Adverse events
During the observation period, adverse events 
were documented for three patients (0.5%). In two 
cases there were more information available. The 
first patient was a child and affected by pharyngi-
tis and snoring. The second patient was an adult 
COPD patient. In this case, the described events 
were irritant cough, hoarseness and “vibration of 
the vocal cords”. Both patients used an EH and 
in both cases the medication was permanently 
discontinued. 
Discussion
Asthma and COPD are common diseases of 
the airways and lungs that have a major impact on 
the health of the population. The mainstay of treat-
ment is by inhalation of medication to the site of 
the disease process [14]. Proper inhaler technique 
is crucial for effective management of asthma and 
COPD. Incorrect usage of inhalers may result in 
diminished therapeutic effect, poor control of 
symptoms and thereby insufficient disease man-
agement [6, 7]. Several authors have compared 
inhaler competences, inhaler usage, and patient 
satisfaction with different inhalers [5, 7, 9−11]. 
Meta-analyses indicate that when patients can 
apply the correct inhalation technique, all in-
halers can achieve the same therapeutic effects, 
although different metered or delivered doses are 
required [16, 17]. The relative effectiveness of 
delivery methods does not provide a clear basis 
for selecting one device over another. Patient’s 
preferences also play an important role when pre-
scribing an inhaler [18]. The literature highlights 
that dose emission from EH is fairly consistent 
irrespective of the inhalation technique used 
by patients of all age groups. Clinical studies 
have shown equivalence of this device to those 
frequently prescribed and that it is preferred by 
many patients [10, 11, 19, 20]. The limitation 
of these studies was that most of the included 
patients with airway diseases have used inhaler 
devices previously and had a good idea about 
inhalation manoeuvres in general. In this study, 
inhaler usage and patient satisfaction was investi-
gated with children and adult/adolescent patients 
with asthma or COPD that had no or only few 
experiences with inhalation devices. Altogether, 
more than 500 patients were included and they 
represent a wide range of age (3−88 years) and 
different educational background. The possible 
tendency for people with higher graduation to start 
certain therapies as well as participation in vari-
ous studies may account for the noticeably high 
percentage of patients with higher graduations en-
rolled in this study. On the other hand, physicians 
may have been prone to ask patients with higher 
education to participate in such studies because 
they supposed that those patients would show 
a better compliance. There were no limitations 
concerning the other inhalation devices. 
Inhaler training was easier with EH in all pa-
tient groups. A second or third instruction of the 
usage of EH was necessary only for 39.8% of the 
children, 35.1% of the adult/adolescent patients, 
whereas 46.9% of the children and 47.7% of the 
adult/adolescent patients with other inhalers 
needed a repetition of the inhaler training. Inter-
estingly, for more than 85.0% of the patients in all 
patient groups the physicians reported that the 
instruction manual was comprehensible. These 
findings are consistent with the suggestion that 
the quality of initial instruction is of paramount 
importance and that written instruction alone is 
inadequate in teaching correct inhalation tech-
nique. In addition, it is necessary to check the re-
sults of the training at regular intervals. Verbal in-
struction and technique assessment and reassess-
ment are essential for patients to achieve proper 
technique, especially at therapy start [21, 22]. 
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This is consistent with the results of our study. 
Assessment of the inhaler usage by the physi-
cian was conducted 2 weeks and 8 weeks after 
the initial training. The usability of the inhaler 
in the patient’s life increased during this time 
whereas the occurrence of difficulties in inhaler 
handling decreased for all used inhalation de-
vices. In this context, also the compliance of the 
patients slightly increased during the observation 
period in all patient groups except the children 
with other inhalers. However, inhaler usability 
as well as patient’s compliance were assessed 
better by the investigators when the patients 
used an EH. The same could be found in the pa-
tient’s questionnaires. Overall, the assessment of 
inhaler usage of EH was significantly better than 
the evaluation of other inhalation devices. No 
significant differences could be found for the In-
haler Usage Score documented by the children as 
well as in the COPD patient group, although the 
scores were similar to the scores documented by 
the adult patients in total and the adult asthma 
patients. It can be suggested that this was a result 
of the smaller number of participating children 
and COPD patients. The general assessment of 
EH was also clearly better. In addition, there were 
less inconvenient features of EH than of other 
inhalers with the same inhalation frequency. 
Nevertheless, verbal support of the patients at 
visit 1 and visit 2 as well as daily practice led 
to an improvement of the assessment during the 
study in general. Similar to the decreased number 
of patients with difficulties in inhaler handling 
at visit 2 in comparison with visit 0, the Inhaler 
Usage Score and thereby the general assessment 
of all used inhalers increased.
One limitation of this study was surely the 
lack of clinical parameters to evaluate the effec-
tiveness of treatment. But it has been suggested 
that the ease of use of an inhaler device may 
correlate with inhaler competence and thereby 
with adherence to treatment [7]. A device that is 
easy to teach to use correctly might also be bet-
ter suited for children and elderly patients who 
may find learning new skills difficult [23]. In the 
present study, there were no clear differences in 
the assessment of the inhaler by the children in 
comparison to the adult patients. The physicians 
reported for 88.0% of the children that used an 
EH and 71.6% of the children with other inhala-
tion devices that it was very easy or fairly easy 
to teach the correct use of the inhaler, in the case 
of the adult patients the same was documented 
for 81.6% with an EH and 64.8% with other 
inhalers. These results actually suggest that it 
was easier to teach children the correct use of 
the inhalers.
One noticeable finding was also the differ-
ences in physician’s and patient’s assessment of 
inhaler usage between patients with asthma and 
those who were affected by COPD. The physicians 
reported very easy or fairly easy inhaler training 
for 80.2% of the patients with asthma and for only 
56.5% of the patients with COPD. 56.5% of the 
patients with COPD needed a repetition of the in-
haler training but only 35.4% of the patients with 
asthma. Inhaler Usage Score as well as general 
assessment of the inhaler by the COPD patients 
were worse than the evaluations documented by 
asthma patients irrespective of the used inhaler. 
There are indications that patients with COPD 
are unable to use a pressurized metered dose 
inhaler (pMDI) correctly. Common errors include 
inadequate coordination in inspiration and ac-
tuation and inability to achieve a high enough 
inspiratory flow rate. One study with Accuhalers 
and Turbuhalers also showed that patients with 
severe COPD were less likely to achieve a high 
enough inspiratory rate to activate the inhaler, 
even after instruction [24]. Other authors demon-
strated that asthmatic patients had a lower risk 
of critical errors than COPD patients, but this 
relationship disappeared after adjustment of de-
vice, age and level of instruction [7]. It was also 
highlighted that the better results in asthmatic 
patients did not match the results observed in 
COPD patients despite proper instructions on 
inhalation technique in both patient groups [25]. 
In addition to this, both age and COPD duration 
are associated with cognitive decline. Cognitive 
disorders, especially memory problems, can also 
lead to non-adherence in patients with COPD [26]. 
The present study was primarily conducted 
to validate a questionnaire that can be used for 
assessing a successful inhalation technique and 
the compliance of the patients in daily practice. 
Analyses of correlation and internal consistency 
showed that all patient groups understood and used 
the questionnaires correctly and it was suitable for 
children as well as elderly patients. The items in the 
questionnaire reflected the factors that play an im-
portant role for the choice of the patients for one or 
another inhalation device, such as handling, clean-
ing, size, weight, ease and success of inhalation.
Conclusion
The results of this study are similar to those 
found by other authors that compared inhaler 
competence and patient satisfaction with EH 
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and other inhalers. Keeping in mind the inherent 
variability among patients, it may be preferable 
that inhalers should be matched to the patient. 
It is also recommended that only one type of 
inhaler should be prescribed. According to the 
patient’s preferences, the best inhaler should 
be portable, easy to use and demonstrate dosing 
accuracy and consistency over a wide range of 
inspiratory flows. The results of this study show 
that investigators found EH easy to teach and the 
patients found it easy to use and their satisfaction 
with the device was high in comparison to other 
inhalation devices. Thus, EH can be matched to 
many patients already at the therapy start. In ad-
dition, the high consistency of the received data 
and large association of the assessment of the 
inhaler usage and the general assessment of the 
inhaler indicate that the used questionnaires were 
appropriate tools to examine usage and usability 
of inhaler devices for patients of all age groups. 
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